Sanofi says any offer for Horizon Therapeutics, if made, will be in cash
Reuters
Published Dec 02, 2022 07:34
Updated Dec 02, 2022 14:47
By Dominique Vidalon
PARIS (Reuters) -French drugmaker Sanofi (EPA:SASY) said on Friday that if it decides to bid for biotech company Horizon Therapeutics Plc, it would do so in cash.
Horizon Therapeutics Plc, which has a market capitalization of about $18 billion, is in talks with Amgen Inc (NASDAQ:AMGN), Sanofi and Johnson & Johnson (NYSE:JNJ) unit Janssen Global Services over potential takeover offers.
"Any offer for Horizon Therapeutics Plc, if made, would be in cash, as required by Rule 2.12 of the Takeover Rules," Sanofi said in a statement.
"There is no certainty that any offer will be made, nor as to terms on which any such offer may be made, if forthcoming," it added.
Shares in Sanofi fell after its statement and were down more than 2% at 85.58 euros at 1100 GMT.
Horizon, which makes drugs for rare, autoimmune and severe inflammatory diseases, has said there is no certainty that it will receive a takeover offer.
UBS said in an analyst note that a deal "would be doable and would not screen badly in terms of P&L impact", but it was debatable whether it should be done.
While acquiring Horizon would add a mixed portfolio of specialty drugs to Sanofi's roster, it would not address the French company's need to develop its drug pipeline and improve its productivity from research and development, UBS said.
Sanofi has made several large-scale takeover deals in recent years, and earlier this year it completed the buyout of immuno-oncology company Amunix Pharmaceuticals for around $1 billion.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.